These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20007620)

  • 21. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
    Furst DE; Fleischmann R; Kopp E; Schiff M; Edwards C; Solinger A; Macri M;
    J Rheumatol; 2005 Dec; 32(12):2303-10. PubMed ID: 16331754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When to initiate and discontinue biologic treatments for rheumatoid arthritis?
    Chatzidionysiou K; van Vollenhoven RF
    J Intern Med; 2011 Jun; 269(6):614-25. PubMed ID: 21261760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
    Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
    Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials: how to cope with medical needs, ethics and timelines.
    Rubbert-Roth A; Burmester GR
    Ann Rheum Dis; 2010 Jan; 69(1):1-3. PubMed ID: 20007619
    [No Abstract]   [Full Text] [Related]  

  • 28. Patient-tailored therapy in rheumatoid arthritis: an editorial review.
    Scherer HU; Dörner T; Burmester GR
    Curr Opin Rheumatol; 2010 May; 22(3):237-45. PubMed ID: 20177384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comment on: 'comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial' by Qian-wen et al.
    Landewé RB; van der Heijde D
    Ann Rheum Dis; 2014 Oct; 73(10):e62. PubMed ID: 25013090
    [No Abstract]   [Full Text] [Related]  

  • 30. The TRIFRA trial: efforts employed to minimise expectation bias.
    Lv QW; Zhang W; Shi Q; Zheng WJ; Lipsky PE; Zhang X
    Ann Rheum Dis; 2014 Nov; 73(11):e67. PubMed ID: 25057182
    [No Abstract]   [Full Text] [Related]  

  • 31. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis.
    Estellat C; Ravaud P
    Arch Intern Med; 2012 Feb; 172(3):237-44. PubMed ID: 22332155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paying attention to the preciseness of conclusion.
    Yuan K; Chen J; Li T; Xu A
    Ann Rheum Dis; 2014 Nov; 73(11):e66. PubMed ID: 25038235
    [No Abstract]   [Full Text] [Related]  

  • 33. A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors.
    Yazici Y; Yazici H
    Ann Rheum Dis; 2007 Jan; 66(1):124-7. PubMed ID: 16831828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of head-to-head study designs in rheumatoid arthritis.
    R F; R L; J S S
    Semin Arthritis Rheum; 2016 Dec; 46(3):279-285. PubMed ID: 27692967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. To switch or to change class-the biologic dilemma in rheumatoid arthritis.
    Villeneuve E; Haraoui B
    Nat Rev Rheumatol; 2010 May; 6(5):301-5. PubMed ID: 20386564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunomodulatory therapy improves quality of life with rheumatoid arthritis].
    Graninger W
    Z Rheumatol; 2010 May; 69(3):210-2. PubMed ID: 20309699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized controlled trial design in rheumatoid arthritis: the past decade.
    Strand V; Sokolove J
    Arthritis Res Ther; 2009; 11(1):205. PubMed ID: 19232061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring effectiveness of drugs in observational databanks: promises and perils.
    Krishnan E; Fries JF
    Arthritis Res Ther; 2004; 6(2):41-4. PubMed ID: 15059263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New approaches to trials of antirheumatic drugs in rheumatoid arthritis.
    Ward JR
    J Clin Pharmacol; 1975 Apr; 15(4 Pt. 2):367-72. PubMed ID: 1127137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized controlled trials and real-world data: differences and similarities to untangle literature data.
    Monti S; Grosso V; Todoerti M; Caporali R
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii54-vii58. PubMed ID: 30289534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.